Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Mato AR"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-16 z 16
    Tytuł:
    Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia
    Autorzy:
    Rhodes JM
    Mato AR
    Pokaż więcej
    Temat:
    chronic lymphocytic leukemia
    small lymphocytic lymphoma
    btk inhibitor
    zanubrutinib
    Therapeutics. Pharmacology
    RM1-950
    Źródło:
    Drug Design, Development and Therapy, Vol Volume 15, Pp 919-926 (2021)
    Opis pliku:
    electronic resource
    Relacje:
    https://www.dovepress.com/zanubrutinib-bgb-3111-a-second-generation-selective-covalent-inhibitor-peer-reviewed-article-DDDT; https://doaj.org/toc/1177-8881
    Dostęp URL:
    https://doaj.org/article/4c33a7594a4f4558881c8228cf06ee45  Link otwiera się w nowym oknie
    Czasopismo naukowe
    Szczegóły
    Tytuł:
    Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data
    Autorzy:
    Isaac K
    Mato AR
    Pokaż więcej
    Temat:
    acalabrutinib
    btk inhibitors
    cll
    treatment naïve cll
    relapsed refractory cll
    ibrutinib toxicity
    Neoplasms. Tumors. Oncology. Including cancer and carcinogens
    RC254-282
    Źródło:
    Cancer Management and Research, Vol Volume 12, Pp 2079-2085 (2020)
    Opis pliku:
    electronic resource
    Relacje:
    https://www.dovepress.com/acalabrutinib-and-its-therapeutic-potential-in-the-treatment-of-chroni-peer-reviewed-article-CMAR; https://doaj.org/toc/1179-1322
    Dostęp URL:
    https://doaj.org/article/362fed3d0ff642eba452cbf97e7eeb3e  Link otwiera się w nowym oknie
    Czasopismo naukowe
    Szczegóły
    Tytuł:
    Nadbiskup Stepinac o sibinjskim žrtvama i mise zadušnice za njih u crkvama Zagrebačke nadbiskupije u veljači i ožujku 1935. godine
    Autorzy:
    Mato Artuković
    Pokaż więcej
    Temat:
    the Sibinj victims 1935
    Archbishop Alojzije Stepinac and the Sibinj victims
    memorial mass services in Zagreb and other parishes of the Zagreb Archdiocese
    songs and cries at the memorial masses
    Philosophy. Psychology. Religion
    Źródło:
    Diacovensia, Vol 26, Iss 4, Pp 583-607 (2018)
    Opis pliku:
    electronic resource
    Relacje:
    https://hrcak.srce.hr/214073; https://doaj.org/toc/1330-2655; https://doaj.org/toc/1849-014X
    Dostęp URL:
    https://doaj.org/article/d4e8858f480741599c517cce409189d9  Link otwiera się w nowym oknie
    Czasopismo naukowe
    Szczegóły
    Tytuł:
    Ustavni okvir djelovanja Ustavnog suda Republike Hrvatske za ispitivanje i ocjenjivanje ustavnosti pravnih praznina
    Autorzy:
    Mato Arlović
    Pokaż więcej
    Temat:
    pravne praznine
    praćenje ostvarivanja ustavnosti i zakonitosti
    nadzor nad donošenjem propisa za izvršavanje Ustava
    zakona i drugih propisa
    ustavna tužba
    ljudska prava i temeljne slobode
    Law
    Źródło:
    Zbornik Radova Pravnog Fakulteta u Splitu, Vol 54, Iss 1, Pp 255-281 (2017)
    Opis pliku:
    electronic resource
    Relacje:
    https://hrcak.srce.hr/file/259511; https://doaj.org/toc/0584-9063; https://doaj.org/toc/1847-0459
    Dostęp URL:
    https://doaj.org/article/5bc6e014197b4bbb865eb16a6c4a6ee3  Link otwiera się w nowym oknie
    Czasopismo naukowe
    Szczegóły
    Tytuł:
    Constitutional grounds of Croatia’s Constitutional Court activity against legal gaps
    Autorzy:
    Mato Arlović
    Pokaż więcej
    Temat:
    legal gaps
    supervision over bringing in regulations for implementing the Constitution
    laws and other regulations
    constitutional lawsuits
    human rights and fundamental freedoms
    rule of law
    Law
    Źródło:
    Zbornik Radova Pravnog Fakulteta u Splitu, Vol 54, Iss 1, Pp 255-281 (2017)
    Opis pliku:
    electronic resource
    Relacje:
    http://hrcak.srce.hr/file/259511; https://doaj.org/toc/0584-9063; https://doaj.org/toc/1847-0459
    Dostęp URL:
    https://doaj.org/article/11f2b820bb4f427d8ee2f88b1963aed8  Link otwiera się w nowym oknie
    Czasopismo naukowe
    Szczegóły
    Tytuł:
    Right to Freedom of Speech and Expression (constitutional legal framework and Constitutional Court practice in the Republic of Croatia)
    Autorzy:
    Mato Arlović
    Pokaż więcej
    Temat:
    freedom
    freedom of speech and expression
    constitutional legal framework
    principle viewpoints
    human rights and freedoms
    Law
    Źródło:
    Zbornik Radova Pravnog Fakulteta u Splitu, Vol 53, Iss 2, Pp 377-411 (2016)
    Opis pliku:
    electronic resource
    Relacje:
    http://www.pravst.hr/dokumenti/zbornik/2016120/zb201602_377.pdf; https://doaj.org/toc/0584-9063; https://doaj.org/toc/1847-0459
    Dostęp URL:
    https://doaj.org/article/1f83c88d3c334207be621a177cf9917a  Link otwiera się w nowym oknie
    Czasopismo naukowe
    Szczegóły
    Tytuł:
    Pravo na slobodu izražavanja misli (ustavnopravni okvir i ustavnosudska praksa u Republici Hrvatskoj)
    Autorzy:
    Mato Arlović
    Pokaż więcej
    Temat:
    sloboda
    sloboda mišljenja i izražavanja misli
    ustavnopravni okvir
    načelna stajališta
    ljudska prava i slobode
    Law
    Źródło:
    Zbornik Radova Pravnog Fakulteta u Splitu, Vol 53, Iss 2, Pp 377-411 (2016)
    Opis pliku:
    electronic resource
    Relacje:
    https://hrcak.srce.hr/file/232411; https://doaj.org/toc/0584-9063; https://doaj.org/toc/1847-0459
    Dostęp URL:
    https://doaj.org/article/595f2106a038401d994ee5f277a3fc47  Link otwiera się w nowym oknie
    Czasopismo naukowe
    Szczegóły
    Tytuł:
    Mutual relations between the Constitutional Court of the Republic of Croatia and judicial powers in the Republic of Croatia
    Autorzy:
    Mato Arlović
    Pokaż więcej
    Temat:
    constitutional adjudication
    constitutional court
    judicial power
    relationship between the constitutional court and judicial powers
    constitutional state
    rule of law
    rule of constitutional law
    the Constitution
    constitutional lawsuit
    Law
    Źródło:
    Zbornik Radova Pravnog Fakulteta u Splitu, Vol 52, Iss 2, Pp 369-405 (2015)
    Opis pliku:
    electronic resource
    Relacje:
    http://www.pravst.hr/dokumenti/zbornik/2015116/zb201502_369.pdf; https://doaj.org/toc/0584-9063; https://doaj.org/toc/1847-0459
    Dostęp URL:
    https://doaj.org/article/b87743b1b3954f1cab2344507a1bbf42  Link otwiera się w nowym oknie
    Czasopismo naukowe
    Szczegóły
    Tytuł:
    Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.
    Autorzy:
    Montoya S; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
    Bourcier J; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Noviski M; Nurix Therapeutics, San Francisco, CA, USA.
    Lu H; Nurix Therapeutics, San Francisco, CA, USA.
    Thompson MC; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Chirino A; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
    Jahn J; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
    Sondhi AK; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
    Gajewski S; Nurix Therapeutics, San Francisco, CA, USA.
    Tan YSM; Nurix Therapeutics, San Francisco, CA, USA.
    Yung S; Nurix Therapeutics, San Francisco, CA, USA.
    Urban A; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; K.G. Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
    Wang E; The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
    Han C; The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
    Mi X; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Kim WJ; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Sievers Q; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Auger P; Nurix Therapeutics, San Francisco, CA, USA.
    Bousquet H; Nurix Therapeutics, San Francisco, CA, USA.
    Brathaban N; Nurix Therapeutics, San Francisco, CA, USA.
    Bravo B; Nurix Therapeutics, San Francisco, CA, USA.
    Gessner M; Nurix Therapeutics, San Francisco, CA, USA.
    Guiducci C; Nurix Therapeutics, San Francisco, CA, USA.
    Iuliano JN; Nurix Therapeutics, San Francisco, CA, USA.
    Kane T; Nurix Therapeutics, San Francisco, CA, USA.
    Mukerji R; Nurix Therapeutics, San Francisco, CA, USA.
    Reddy PJ; Nurix Therapeutics, San Francisco, CA, USA.
    Powers J; Nurix Therapeutics, San Francisco, CA, USA.
    Sanchez Garcia de Los Rios M; Nurix Therapeutics, San Francisco, CA, USA.
    Ye J; Nurix Therapeutics, San Francisco, CA, USA.
    Barrientos Risso C; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
    Tsai D; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
    Pardo G; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
    Notti RQ; Laboratory of Molecular Electron Microscopy, Rockefeller University, New York, NY, USA.
    Pardo A; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
    Affer M; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
    Nawaratne V; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
    Totiger TM; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
    Pena-Velasquez C; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Rhodes JM; Division of Hematology-Oncology, Department of Medicine at Zucker School of Medicine at Hofstra/Northwell, CLL Research and Treatment Center, Lake Success, NY, USA.
    Zelenetz AD; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Alencar A; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
    Roeker LE; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Mehta S; Gene Editing and Screening Core Facility, Department of Cancer Biology and Genetics, Memorial Sloan Kettering Institute and Cancer Center, New York, NY, USA.
    Garippa R; Gene Editing and Screening Core Facility, Department of Cancer Biology and Genetics, Memorial Sloan Kettering Institute and Cancer Center, New York, NY, USA.
    Linley A; Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
    Soni RK; Proteomics and Macromolecular Crystallography Shared Resource, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.
    Skånland SS; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; K.G. Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
    Brown RJ; Nurix Therapeutics, San Francisco, CA, USA.
    Mato AR; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Hansen GM; Nurix Therapeutics, San Francisco, CA, USA.
    Abdel-Wahab O; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Taylor J; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
    Pokaż więcej
    Źródło:
    Science (New York, N.Y.) [Science] 2024 Feb 02; Vol. 383 (6682), pp. eadi5798. Date of Electronic Publication: 2024 Feb 02.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Agammaglobulinaemia Tyrosine Kinase*/genetics
    Agammaglobulinaemia Tyrosine Kinase*/metabolism
    Ikaros Transcription Factor*/metabolism
    Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
    Leukemia, Lymphocytic, Chronic, B-Cell*/genetics
    Protein Kinase Inhibitors*/pharmacology
    Protein Kinase Inhibitors*/therapeutic use
    Proteolysis*/drug effects
    Drug Resistance, Neoplasm*/drug effects
    Humans ; Mutation ; Phosphorylation ; Signal Transduction
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality.
    Autorzy:
    Stahl M; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Narendra V; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Jee J; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Derkach A; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Maloy M; Department of Health Informatics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Geyer MB; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
    Mato AR; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
    Roeker LE; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
    Tallman MS; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
    Shah GL; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.; Department of Medicine, Memorial Sloan Kettering Cancer Center, Adult Bone Marrow Transplantation Service, New York, NY, USA.
    Daniyan A; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
    Goldberg AD; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2021 Aug; Vol. 62 (8), pp. 1940-1948. Date of Electronic Publication: 2021 Jun 28.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    COVID-19*
    Leukemia, Myeloid, Acute*/complications
    Leukemia, Myeloid, Acute*/epidemiology
    Leukemia, Myeloid, Acute*/therapy
    Neutropenia*/epidemiology
    Neutropenia*/etiology
    Adult ; COVID-19 Testing ; Humans ; Risk Factors ; SARS-CoV-2
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
    Autorzy:
    Cuneo A; Hematology, Department of Medical Sciences, St. Anna University Hospital, Ferrara, Italy.
    Mato AR; Division of Hematological Oncology, CLL Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Rigolin GM; Hematology, Department of Medical Sciences, St. Anna University Hospital, Ferrara, Italy.
    Piciocchi A; Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.
    Gentile M; Department of Onco-Hematology, Hematology Unit, A.O. of Cosenza, Cosenza, Italy.
    Laurenti L; Department of Radiological, Radiotherapeutic and Hematological Sciences, Fondazione Policlinico Universitario 'A. Gemelli' IRCCS, Rome, Italy.
    Allan JN; Weill Cornell Medicine, New York, NY, USA.
    Pagel JM; Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA, USA.
    Brander DM; Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC, USA.
    Hill BT; Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
    Winter A; Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
    Lamanna N; Columbia University Medical Center, New York, NY, USA.
    Tam CS; Peter McCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.
    Jacobs R; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC, USA.
    Lansigan F; Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
    Barr PM; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
    Shadman M; Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, USA.
    Skarbnik AP; Lymphoproliferative Disorders Program, Novant Health Cancer Institute, Charlotte, NC, USA.
    Pu JJ; SUNY Upstate Medical University, SUNY Upstate Medical University, Syracuse, NY, USA.
    Sehgal AR; University of Pittsburgh, Pittsburgh, PA, USA.
    Schuster SJ; Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.
    Shah NN; Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
    Ujjani CS; Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, USA.
    Roeker L; Division of Hematological Oncology, CLL Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Orlandi EM; Hematology Unit, IRCCS Policlinico San Matteo, Pavia, Italy.
    Billio A; Hematology and Transplant Unit, San Maurizio Hospital, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy.
    Trentin L; Hematology and Clinical Immunology, Department of Medicine, University of Padua, Padua, Italy.
    Spacek M; Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
    Marchetti M; Oncology Unit, Cardinal Massaia Hospital, Asti, Italy.
    Tedeschi A; Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
    Ilariucci F; Hematology, Azienda USL-IRCCS, Reggio Emilia, Italy.
    Gaidano G; Division of Hematology, Department of Translational Medicine, University of eastern Piedmont, Novara, Italy.
    Doubek M; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
    Farina L; Hematology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy.
    Molica S; Hematology Unit, A. Pugliese Hospital, Azienda Ospedaliera Pugliese Ciaccio, Catanzaro, Italy.
    Di Raimondo F; Catania Università di Catania, Cattedra di Ematologia, Catania, Italy.
    Coscia M; Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
    Mauro FR; Hematology, Department of Translational and Precision Medicine, 'Sapienza' University, Rome, Italy.
    de la Serna J; Hematology Unit, Hospital Universitario, Madrid, Spain.
    Medina Perez A; Hospital Costa del Sol, Marbella, Spain.
    Ferrarini I; Hematology, Department of Cell Therapy and Hematology, University Hospital, Verona, Italy.
    Cimino G; Department of Translational and Precision Medicine, University 'La Sapienza', UOC di Ematologia con Trapianto, Ospedale S. Maria Goretti, Latina, Italy.
    Cavallari M; Hematology, Department of Medical Sciences, St. Anna University Hospital, Ferrara, Italy.
    Cucci R; Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.
    Vignetti M; Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.
    Foà R; Hematology, Department of Translational and Precision Medicine, 'Sapienza' University, Rome, Italy.
    Ghia P; Strategic Research Program on CLL, Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Università Vita-Salute San Raffaele, Milan, Italy.
    Pokaż więcej
    Corporate Authors:
    GIMEMA, European Research Initiative (ERIC) on CLL, US study group
    Źródło:
    Cancer medicine [Cancer Med] 2020 Nov; Vol. 9 (22), pp. 8468-8479. Date of Electronic Publication: 2020 Sep 24.
    Typ publikacji:
    Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Adenine/*analogs & derivatives
    Antineoplastic Agents, Alkylating/*therapeutic use
    Antineoplastic Agents, Immunological/*therapeutic use
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Bendamustine Hydrochloride/*therapeutic use
    Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
    Piperidines/*therapeutic use
    Protein Kinase Inhibitors/*therapeutic use
    Rituximab/*therapeutic use
    Adenine/adverse effects ; Adenine/therapeutic use ; Aged ; Antineoplastic Agents, Alkylating/adverse effects ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bendamustine Hydrochloride/adverse effects ; Disease Progression ; Europe ; Female ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis ; Leukemia, Lymphocytic, Chronic, B-Cell/mortality ; Male ; Middle Aged ; Piperidines/adverse effects ; Progression-Free Survival ; Protein Kinase Inhibitors/adverse effects ; Retrospective Studies ; Rituximab/adverse effects ; Time Factors ; United States
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States.
    Autorzy:
    Goyal RK; a RTI Health Solutions , Research Triangle Park , NC , USA.
    Nagar SP; a RTI Health Solutions , Research Triangle Park , NC , USA.
    Kabadi SM; b AstraZeneca , Gaithersburg , MD , USA.
    Kaye JA; c RTI Health Solutions , Waltham , MA , USA.
    Seal B; b AstraZeneca , Gaithersburg , MD , USA.
    Mato AR; d Department of Medicine, Division of Hematological Malignancies , Memorial Sloan Kettering Cancer Center , New York , NY , USA.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2019 Apr; Vol. 60 (4), pp. 955-963. Date of Electronic Publication: 2018 Oct 02.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Cost of Illness*
    Health Resources*
    Insurance, Health*
    Lymphoma, Mantle-Cell/*epidemiology
    Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Comorbidity ; Female ; Humans ; Lymphoma, Mantle-Cell/diagnosis ; Lymphoma, Mantle-Cell/therapy ; Male ; Middle Aged ; Practice Patterns, Physicians' ; Proportional Hazards Models ; Public Health Surveillance ; Risk Factors ; United States/epidemiology ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
      Wyświetlanie 1-16 z 16

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies